AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a distinct biologic subtype of AML that represents 25–34% of all AML diagnoses and associates with especially inferior outcomes compared to non-MRC AML. Typically, patients with AML-MRC experience low remission rates follo...
Main Authors: | Kristin L. Koenig, Kieran D. Sahasrabudhe, Audrey M. Sigmund, Bhavana Bhatnagar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/11/8/845 |
Similar Items
-
Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
by: Sarah Bertoli, et al.
Published: (2019-07-01) -
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
by: Chen EC, et al.
Published: (2018-06-01) -
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
by: Lalit S Raut
Published: (2015-01-01) -
ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia‐related changes and normal karyotype
by: Concepción Prats‐Martín, et al.
Published: (2020-06-01) -
CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report
by: Ruth M. Urbantat, et al.
Published: (2021-04-01)